The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
Cardinal Health notified the state on Feb. 3 that it laid off 37 workers at the end of January and plans to lay off 12 more
effective April 3.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
Batesville maker of hospital equipment meets analysts’ expectations, then raises full-year profit forecast.
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
Massachusetts’ election of a Republican senator has put health reform legislation on life support. But for the health
care industry, reform is a reality that isn’t going to die.
Struggling West Lafayette life science contract research firm will search nationally for a new permanent leader.
Analysts worry about dive in already paltry sales of new blood thinner Effient
But excluding special charges, Warsaw-based orthopedic implant maker grows profits 5 percent, easily beating expectations
of Wall
Street.
Drug distribution firm that acquired former WellPoint subsidiary plans to consolidate specialty pharmacy work at local
airport facility.
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Associated X-Ray Services relocates headquarters from South Bend to Indianapolis and also announces the company has changed
its name to AXS Imaging.
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
The management change comes as the Indianapolis company’s diabetes market share has been sliding. Roche says successor will
be named “shortly.”
John J. Greisch was most recently president of international operations at Baxter International Inc.
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
RealMed enjoys a nearly 99-percent renewal rate among its current customers and attracted 4,000 new doctors
in 2009. Employment at the company is rising after a steady decline.
